NSW Government has opened a registration of interest (ROI) process for an operator, to establish a commercial-scale GMP Pilot RNA manufacturing facility. This single-site ecosystem has the ambition for leadership through manufacture across sRNA, mRNA and lipidnanoprotein encapsulation.
According to the NSW Government, it maintains its ‘strategic focus on health R&D and is committed to an investment of $96 million for an RNA Pilot Manufacturing Facility’. The centralised manufacturing facility will be focused on clinical trial-scale manufacture and will provide a home for the further development of local R&D success accelerating the translation of NSW’s research strengths into a sustainable commercial RNA therapeutics and products.
This investment will ‘further leverage this strength in NSW and aims to achieve the NSW Government’s ambition of being a global leader in RNA R&D’.
The NSW Government’s ROI will be used to identify suitable companies to progress to the expression of interest (EOI) phase, which will commence late May 2022.
The successful company that progresses through the ROI phase, will contribute to the growth of RNA R&D and manufacturing capability in NSW, and have:
- The ability to run and operate an RNA facility at GMP and TGA level;
- The commitment to building, and being part of, a thriving RNA R&D ecosystem; and,
- The commitment to engaging with the RNA R&D ecosystem in building background IP, translating fundamental R&D to commercial and health outcomes for NSW – capitalising on the significant research expertise in NSW in RNA technologies and provide a path to further develop these products through the clinical trial process.
The ROI closes on 12 May 2022. To find more about the ROI, click here. The ROI is supported by Biointelect and the Centre for Biopharmaceutical Excellence (CBE), if you have any questions about the ROI please feel free to contact Leah Goodman, Senior Consultant at Biointelect.